MARINA BOTA: Open Payments
NPI 1164430831 · BLOOMINGTON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,847 in 105 payments from 17 companies in 2025. Trend: 2023 $990 · 2024 $1,004 · 2025 $1,847
Food & beverage: $1,735Education: $111
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 26 | $384 |
| Teva Pharmaceuticals USA, Inc. | 8 | $244 |
| E.R. Squibb & Sons, L.L.C. | 14 | $240 |
| Lundbeck LLC | 14 | $180 |
| ABBVIE INC. | 12 | $179 |
| Neurocrine BioSciences, Inc. | 6 | $123 |
| Vanda Pharmaceuticals Inc. | 4 | $93 |
| Axsome Therapeutics, Inc. | 2 | $63 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $62 |
| Janssen Pharmaceuticals, Inc | 4 | $61 |
Products named: REXULTI, COBENFY, VRAYLAR, ABILIFY MAINTENA, INGREZZA, HETLIOZ, AUSTEDO XR, Auvelity.
Industry payments across IN — which companies pay providers there.
